SEC Form 4 · accession 0001610717-26-000247
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Mancini
Officer — See Remarks
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4 | Jun 16, 2026 | S | 4,615 | $156.1192 | D | 49,975 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes.
- F2This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Includes 43,700 Restricted Stock Units.
- F4Includes 190 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
Remarks
Chief Global Commercialization Officer